Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
J Food Drug Anal. 2018 Apr;26(2S):S12-S25. doi: 10.1016/j.jfda.2018.01.013. Epub 2018 Feb 15.
There is a continued predisposition of concurrent use of drugs and botanical products. Consumers often self-administer botanical products without informing their health care providers. The perceived safety of botanical products with lack of knowledge of the interaction potential poses a challenge for providers and both efficacy and safety concerns for patients. Botanical-drug combinations can produce untoward effects when botanical constituents modulate drug metabolizing enzymes and/or transporters impacting the systemic or tissue exposure of concomitant drugs. Examples of pertinent scientific literature evaluating the interaction potential of commonly used botanicals in the US are discussed. Current methodologies that can be applied to advance our efforts in predicting drug interaction liability is presented. This review also highlights the regulatory science viewpoint on botanical-drug interactions and labeling implications.
存在持续的同时使用药物和植物产品的倾向。消费者经常在不告知医疗保健提供者的情况下自行使用植物产品。由于缺乏对相互作用潜力的了解,人们认为植物产品是安全的,这给提供者和患者的疗效和安全性都带来了挑战。当植物成分调节药物代谢酶和/或转运体从而影响伴随药物的全身或组织暴露时,植物-药物组合可能会产生不良影响。讨论了评估美国常用植物的相互作用潜力的相关科学文献实例。介绍了可用于推进我们预测药物相互作用责任的努力的当前方法。本综述还强调了监管科学对植物-药物相互作用和标签影响的观点。